Copy
This is an extra bulletin from the IBTA to share important news. Find out more about us at www.theibta.org
Can't read this email?
View it in your browser

Forward this to a friend
Share this:
share on Twitter
Like A special announcement from the IBTA on Facebook
Google Plus One Button


IBTA e-Bulletin

Special announcement from the
International Brain Tumour Alliance

Tuesday 13th July 2021

Brain tumours and COVID-19 vaccines 
International survey

Dear Friends,
We would be grateful if you could support a new international survey on COVID-19 vaccines and brain tumour patients.

Last year, the IBTA ran two international surveys examining (1) “Brain tumours and COVID-19: the patient and caregiver experience” and (2) how COVID-19 was affecting brain tumour patient advocacy organisations. The results of these surveys were published in the peer-reviewed journal Neuro-Oncology Advances and can be found here and here. A lay summary of the first survey (“Brain tumours and COVID-19: the patient and caregiver experience”) can also be found via the IBTA website here. We are delighted that the results of these two surveys are proving to be an invaluable data resource for the scientific community and the not-for-profit sector.

Our new survey on COVID-19 vaccines and brain tumour patients is for people over the age of 18 who have been diagnosed with any type of brain tumour (including metastatic brain tumours). The survey will collect data anonymously on, for example, how the coronavirus vaccination programmes in different countries have been offered to brain tumour patients; COVID-19 testing; which vaccines brain tumour patients have received; and vaccine side effects in brain tumour patients.

Please help us distribute this new survey to as many adult patients in the brain tumour community as possible. The survey is available in eight languages (English, French, German, Italian, Japanese, Polish, Spanish and Urdu) and typically takes no more than ten minutes to complete. The deadline for submitting survey responses is 31st August 2021.

 

Sharing the survey

The direct links for all languages are below:
English: https://www.research.net/r/IBTACOVIDVAX
French: https://www.research.net/r/IBTACOVIDVAX?lang=fr
German: https://www.research.net/r/IBTACOVIDVAX?lang=de
Italian: https://www.research.net/r/IBTACOVIDVAX?lang=it
Japanese:  https://www.research.net/r/IBTACOVIDVAX?lang=ja
Polish:  https://www.research.net/r/IBTACOVIDVAX?lang=pl
Spanish: https://www.research.net/r/IBTACOVIDVAX?lang=es

Urdu: https://www.research.net/r/IBTACOVIDVAX-ur - Please note that Urdu can only be accessed via this link.

QR codes: Please feel free to distribute the QR code for the various language versions of the survey, which can be downloaded from the IBTA website here. A separate QR code for the Urdu translation can be found here.
 
Sample social media post for the survey: If you wish to disseminate the survey via your social media channels, here is a suggested post to copy and paste:

Have you or a loved one been affected by a brain tumour? Please complete this short survey on COVID vaccines and adult brain tumour patients: https://www.research.net/r/IBTACOVIDVAX  #braintumour #braintumor #COVIDVaccines #IBTACovidSurvey #supportresearch #BTSM
 
Finally, we are aware that some people had difficulty in submitting their survey results last week due to a technical issue. This has now been resolved.
Thank you very much for disseminating the COVID-19 vaccines and brain tumour patients survey. We greatly appreciate your support.

Facebook
Facebook
Twitter
Twitter
IBTA Website
IBTA Website

ABOUT THE IBTA


Who we are

The International Brain Tumour Alliance was established in 2005. It is a network of support, advocacy and information groups representing brain tumour patients and carers in different countries and also includes researchers, scientists, clinicians and allied health professionals who work in the field of brain tumours.
For more information, please visit www.theibta.org.  

 

Tell us what you think!

We love to hear from you if you have any news that you would like to share with the IBTA community. Just send us an email: chair@theibta.org.
We will do our best to relay as much information as possible to our subscribers via this monthly newsletter and our website. The selection of e-News entries is at the sole discretion of the editors.
Copyright © 2021 The International Brain Tumour Alliance, All rights reserved.

Disclaimer

The International Brain Tumour Alliance (IBTA) makes every effort to be accurate regarding the information contained in this e-News (or in any documents, reports, notes or other material produced for and on behalf of the IBTA to which we provide a link in this e-News).  However, the IBTA accepts no liability for any inaccuracies or omissions herein nor can it accept liability for any loss or damage resulting from any inaccuracy in this information or third party information such as information on websites to which we link. The information contained in this e-News is for educational purposes only and should in no way be taken as a substitute for medical care nor is the information on the IBTA website meant to constitute medical advice or professional services. For medical care and advice, please contact your doctor. Inclusion of clinical trial news does not imply the IBTA’s particular endorsement or not of any trial.

Other websites linked from the IBTA e-News are not under the control of the IBTA. Therefore we take no responsibility for their content. The IBTA has provided these links as a convenience to you and can in no way verify the information, quality, safety or suitability of linked websites.

Any company sponsorship of the IBTA's projects does not imply the IBTA's endorsement of any particular form or forms of therapy, treatment regimen or behaviour. (For further details of our sponsors, please see our Sponsorship Policy).

The views and opinions in the materials included in this e-News may not necessarily be those of the International Brain Tumour Alliance.


unsubscribe from this list    update subscription preferences